Novel Drug Development in Breast Cancer

Panelists: Kimberly L. Blackwell, MD, Duke; Adam M. Brufsky, MD, PhD, University of Pittsburgh;
Joyce A. O’Shaughnessy, MD, US Oncology; Mark D. Pegram, MD, Stanford; Hope S. Rugo, MD, UCSF;
Denise A. Yardley, MD, Sarah Cannon
Published Online: Wednesday, March 26, 2014
For High-Definition, Click
A number of clinical trials are exploring novel treatments for patients with breast cancer across a variety of settings. Recently, the phase III BOLERO-3 trial examined the addition of everolimus to the combination of trastuzumab and vinorelbine in women with HER2-positive metastatic breast cancer. The median progression-free survival with the addition of everolimus was 7 months versus 5.78 months in the placebo group.

Overall, the addition of everolimus resulted in more toxicity with a minimal improvement in efficacy, states Hope S. Rugo, MD. The lack of greater efficacy leads Joyce A. O’Shaughnessy, MD, to question whether the estrogen receptor may have been upregulated by the combination of the HER2 and mTOR inhibitors. This theory calls for further investigation, she believes.

With a variety of new agents becoming available, a larger emphasis is being placed on rapid, adaptive clinical trial design. In the I-SPY 2 trial, multiple drugs are being explored across several cohorts that are based on 10 signatures, such as hormone receptor (HR) status, HER2 status, and MammaPrint risk assessments. Patients are assigned to cohorts and randomized to receive a novel agent with or without standard neoadjuvant chemotherapy. Moreover, Rugo notes, the trial is designed to be flexible, allowing for changes as standards of care evolve.

Following surgery, pathologic complete response (pCR) rates are compared between the patients with each signature to identify a subpopulation most likely to respond. Once identified, larger phase III trials will be formed to confirm the findings.

The first results from the I-SPY 2 trial demonstrated encouraging possibilities for veliparib (ABT-888) in triple-negative breast cancer and neratinib (PB272) in patients who are HER2-positive and HR-negative. Furthermore, Rugo notes, based on the design of the trial, these agents have an 85% Bayesian predictive probability for success in future 300-patient phase III neoadjuvant trials with pCR as a primary endpoint.
View More From This Discussion
Episode 1 Overview of HER2-Targeted Therapies in Breast Cancer
Episode 2 Treating Low-Risk HER2-Positive Breast Cancer
Episode 3 Frontline Pertuzumab for Metastatic Breast Cancer
Episode 4 PIK3CA Mutations in HER2-Positive Breast Cancer
Episode 5 T-DM1 in HER2-Positive Metastatic Breast Cancer
Episode 6 Recommendations for Optimal HER2 Testing in Breast Cancer
Episode 7 Role of Lapatinib in HER2-Positive Breast Cancer
Episode 8 Novel Drug Development in Breast Cancer
Episode 9 Phase III Clinical Trials in HER2-Positive Breast Cancer
Episode 10 Case Study: HER2-Positive Oligometastatic Breast Cancer
Episode 11 Upfront Treatment of HR-Positive MBC
Episode 12 Next Steps for Everolimus in Metastatic Breast Cancer
Episode 13 CDK4/6 Inhibitors in Metastatic Breast Cancer
Episode 14 Chemotherapeutics in Metastatic Breast Cancer
Episode 15 Preventing Skeletal-Related Events in Breast Cancer
Episode 16 Conclusion: Future Direction of Breast Cancer Treatment
Expert Panelists
Dr Adam Brufsky

Adam M. Brufsky, MD, PhD

Professor of Medicine, University of Pittsburgh
Medical Director of the Women’s Cancer Center at Magee-Womens Hospital of UPMC and the University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

Kimberly L. Blackwell, MD

Professor of Medicine
Assistant Professor in Radiation Oncology
Duke Cancer Institute
Durham, North Carolina

Joyce A. O’Shaughnessy, MD

Co-Director, Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology, PA/US Oncology,
Dallas, Texas

Mark D. Pegram, MD

Professor of Medicine (Oncology)
Stanford University Medical Center;
Susy Yuan-Huey Hung Professor;
Associate Director of Clinical Research and Director, Breast Cancer Program, Stanford Cancer Institute, Stanford, California

Hope S. Rugo, MD

Professor of Medicine and Director of the Breast Oncology, Clinical Trials, and Education Program, University of California San Francisco Comprehensive Cancer Center, San Francisco, California

Denise A. Yardley, MD

Senior Investigator, Breast Cancer Research
Sarah Cannon Research Institute, Tennessee Oncology, Nashville, Tennessee
Online CME Activities
Free CME from PER
Community Practice Connections: 8th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Community Practice Connections: 11th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
Evaluating the Neoadjuvant Treatment of Breast Cancer
Cardiology Review/CME Reviews: Volume 31, Number 2
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.
More Reading